Disruptive Technological Advances in Life Science

D-TAILS S.r.l. Società Benefit is an Italian R&D company developing advanced diagnostic technologies for early disease detection, with a focus on oncology and neurodegeneration. The company integrates biosensing, microfluidics, imaging and AI to translate scientific research into scalable healthcare solutions.

Sede:

Soluzione innovativa:
Redefining Early Cancer Detection with hybrid biosensing

Early cancer detection is crucial, yet current methods are costly, invasive, and too complex for population-scale screening.

D-Tails has developed a fast, non-invasive and affordable hybrid biosensor that detects cancer-related volatile organic compounds (VOCs) in urine with over 90% accuracy in pilot lab tests.
By identifying nine specific olfactory receptors for breast and prostate cancer-related VOCs and leveraging a versatile, low-cost platform, our solution offers a reliable, non-invasive, and user-friendly approach to early diagnosis.

This hybrid biosensor is set to transform cancer screening, improving patient compliance and healthcare efficiency. D-Tails is actively expanding partnerships with diagnostic centers and hospitals to scale screening capacity and bring this breakthrough technology to market. Operating in a vast, high-impact sector with minimal competition, we seek strategic investors to accelerate development and global adoption.

The technology is not yet a market-ready product but has reached a consolidated pre-competitive stage suitable for translational development and investor engagement.

Ambito: biotech, digital health, diagnostica
TRL: 4
Brevetto: sì
Funding need: 10M€